• Product NameNMS-P937 (NMS1286937)
• Brief DescriptionInhibitors
• Purification99.76%
• Biological ActivityNMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.
• Target NamePLK inhibitor
• CAS No. 1034616-18-6
• Calculated MW 532.52
• Formulation C24H27F3N8O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1CCN(CC1)C1=CC=C(OC(F)(F)F)C(NC2=NC3=C(CCC4=C3N(CCO)N=C4C(N)=O)C=N2)=C1 |c:25,32,38,40,t:8,10,19,21|
  Pathways:Cell Cycle/Checkpoint
  Receptor:PLK1; PLK2; PLK3
  Boling pt:
  Melting pt:
  Solubility:DMSO:42 mg/mL warmed (78.87 mM)Ethanol:10 mg/mL warmed (18.77 mM)Water<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Beria I, et al. Bioorg Med Chem Lett. 2011, 21(10), 2969-2974.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting